Savara Inc. Common Stock SVRA
i
Market datapartial · fetched 2026-11-12T03:21:27.712Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:57:11.745171761Z
FundamentalsAlpha Vantage · unavailable
Savara Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.99 | 218.4% | 24.7% | |||
| 25Δ | 4.24 | 233.7% | 23.0% | |||
| 30Δ | 4.48 | 249.5% | 21.3% | |||
| 35Δ | 4.72 | 265.2% | 19.6% | |||
| 40Δ | 4.96 | 281.0% | 18.0% | |||
| 45Δ | 6.23 | 535.2% | 25.1% | |||
| 50Δ | 6.46 | 485.5% | 20.9% | |||
| 55Δ | 6.68 | 435.8% | 16.8% | |||
| 60Δ | 6.91 | 386.1% | 12.7% | |||
| 65Δ | 7.21 | 354.5% | 10.1% | |||
| 70Δ | 7.56 | 333.9% | 8.4% | |||
| 75Δ | 7.90 | 313.2% | 6.7% | |||
| 80Δ | 3.86 | 774.9% | 30.5% | 8.25 | 292.5% | 5.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.99
- IV
- 218.4%
- B/E move
- 24.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.24
- IV
- 233.7%
- B/E move
- 23.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.48
- IV
- 249.5%
- B/E move
- 21.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.72
- IV
- 265.2%
- B/E move
- 19.6%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.96
- IV
- 281.0%
- B/E move
- 18.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.23
- IV
- 535.2%
- B/E move
- 25.1%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.46
- IV
- 485.5%
- B/E move
- 20.9%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.68
- IV
- 435.8%
- B/E move
- 16.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.91
- IV
- 386.1%
- B/E move
- 12.7%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.21
- IV
- 354.5%
- B/E move
- 10.1%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.56
- IV
- 333.9%
- B/E move
- 8.4%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.90
- IV
- 313.2%
- B/E move
- 6.7%
80Δ
- Pseudo strike
- 3.86
- IV
- 774.9%
- B/E move
- 30.5%
- Pseudo strike
- 8.25
- IV
- 292.5%
- B/E move
- 5.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 185.27% |
Biotechnology
SYRE
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody…
More →TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare…
More →TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions.…
More →TECH
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is…
More →TECX
Description unavailable
More →TENX
Description unavailable
More →